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Aim To estimate the effect size of concomitant antiepileptic 
therapy on the concentrations of lamotrigine, a drug often 
prescribed in combination with other antiepileptic drugs 
(AED), which can act as enzyme inducers or inhibitors.
Methods A total of 304 patients with epilepsy, aged 18-
70 years, were divided into a lamotrigine monotherapy 
group and groups receiving lamotrigine with AEDs that 
act as enzyme inducers, enzyme inhibitors, or both. We 
compared lamotrigine monotherapy serum concentra-
tions with those where lamotrigine was administered with 
a metabolic inhibitor valproate, metabolic inducers car-
bamazepine, oxcarbazepine, phenobarbital, phenytoin, or 
topiramate, and both an inducer and an inhibitor.
Results Comparison of trough lamotrigine monotherapy 
concentrations and lamotrigine polytherapy concentra-
tions showed an almost similar median concentration in 
case of drug-inducers, and higher lamotrigine concentra-
tion in case of comedication with valproate as an inhibitor. 
A significant difference was confirmed after dose correc-
tion (P < 0.001). Significant positive correlations of lam-
otrigine trough serum concentrations with valproate were 
observed before and after the dose correction (r = 0.480, 
P < 0.001 and r = 0.561, P < 0.001, respectively). Positive cor-
relations between the dose-corrected lamotrigine trough 
concentration and carbamazepine (r = 0.439; P < 0.001) 
or monohydroxy metabolite of oxcarbazepine (MHD) 
(r = 0.675; P < 0.001) were also significant.
Conclusion Higher valproate levels resulted in higher in-
hibition potency and higher lamotrigine levels. Increased 
dose-corrected concentrations of inducers carbamazepine 
and MHD, after the process of induction was finished, did 
not lower lamotrigine concentrations. These findings can 
be of clinical significance for optimal AED dosing.
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Lamotrigine belongs to the second generation of antiepi-
leptic drugs (AEDs) (1,2). Its metabolic interactions were 
recognized during development and before its market-
ing approval. As a result, a significant dose reduction was 
recommended and a wide therapeutic range was recog-
nized in clinical practice (3). Lamotrigine is metabolized 
mainly by uridine-diphosphate-glucuronide transferase 
(UGT) 1A4, mostly to N2-glucuronide and to a minor 
N-5-glucuronide metabolite (4). Elimination of lamotrig-
ine is age-related and highly influenced by liver or kid-
ney function. Enzyme induction by other AEDs, such as 
carbamazepine, phenobarbital, phenytoin, and primi-
done, may result in increased lamotrigine clearance and 
decreased lamotrigine trough concentration, which re-
quires dose corrections (5-7). Oxcarbazepine and topira-
mate may also induce lamotrigine metabolism. Valproate 
is a strong inhibitor of lamotrigine metabolism and may 
cause an increase in lamotrigine concentrations by 200% 
(5-9). According to Johannessen et al (10), lamotrigine 
and valproate pharmacokinetic interactions are classi-
fied as level 2 on the basis of magnitude of alterations 
in serum concentration, requiring caution and possible 
dose adjustments if the combination cannot be avoid-
ed. While lamotrigine metabolism occurs mainly via UG-
T1A4, glucuronidation of valproate is catalyzed primarily 
by UGT2B7 (11,12). UGTs are liable to both inhibition and 
induction, and the pharmacogenetic predisposition of 
UGTs has been broadly investigated in relation to their 
variability in drug metabolism (13,14).
Due to substantial pharmacokinetic variability of lam-
otrigine, there is a need for therapeutic drug monitoring. 
Furthermore, it has been observed that lamotrigine con-
centrations in the reference range, although rather wide, 
are not necessarily therapeutic, optimal, and effective. 
For some patients, individual therapeutic concentrations 
should be established. Our aim was to estimate the extent 
of the influence of other AEDs on lamotrigine concentra-
tions in patients with focal and generalized seizures. This 
approach could help clinicians to estimate the possible 
correlation between drug interactions and disease control 
reflected in the reduced number of attacks and between 
drug interactions and side effects of antiepileptic drugs.
METHODS
Subjects
This retrospective study included a cohort of 304 patients 
(126 men), aged 18-70 years, who were diagnosed as hav-
ing epilepsy with focal or generalized seizures and treated 
at the Referral Centre for Epilepsy, University Hospital Cen-
ter Zagreb (Figure 1). The exclusion criteria were impair-
ment of hepatic and renal function as confirmed by stan-
dard biochemical parameters including urea, creatinine, 
and hepatic enzymes (Table 1). Data sources were patient 
medical histories from the University Hospital Center Za-
greb, Department of Neurology and Department of Labo-
ratory Diagnostics, from 2009 to 2013.
FIGurE 1. Flowchart of lamotrigine-treated patients with epilepsy included in the study.
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Lamotrigine was administered in doses from 50 to 300 
mg/d as monotherapy in 74 patients or in combination 
with valproate (600 to 1500 mg/d) in 92 patients, carbam-
azepine (600-1600 mg/d) in 110 patients, oxcarbazepine 
(600-1800 mg/d) in 47 patients, phenobarbital (100-600 
mg/d) in 78 patients, phenytoin (200-300 mg/d) in 9 pa-
tients or topiramate (50-250 mg/d) in 10 patients. Sever-
al patients were also treated with vigabatrin, gabapentin 
or levetiracetam. According to the known impact of each 
drug on the pharmacokinetics of lamotrigine, patients 
were divided into four groups as follows: patients receiving 
lamotrigine monotherapy, patients receiving lamotrigine 
in combination with a metabolic inhibitor (valproate), pa-
tients receiving lamotrigine in combination with metabol-
ic inducers (carbamazepine, oxcarbazepine, phenobarbital, 
phenytoin, or topiramate), and patients receiving lamotrig-
ine in combination with both an inducer and an inhibitor.
Therapeutic drug monitoring
In the Referral Centre for Epilepsy, serum concentrations 
of antiepileptic drugs are routinely measured in each pa-
tient. This implies that all measurements were available for 
all patients included in the study.
One blood sample per patient was collected after a steady 
state concentration of the drug was achieved, ie, not less 
than 21 days from start of therapy. Blood samples were ob-
tained in the morning, 12 hours after bedtime dose and 
before the morning dose (trough value). Serum concen-
trations of lamotrigine, carbamazepine, 10-monohydroxy 
metabolite of oxcarbazepine (MHD), and phenytoin were 
measured by high performance liquid chromatography 
methods with a diode array detector (Shimadzu, Kyoto, 
Japan). Sample and internal standard (chloramphenicol 
100 µg/ml) were extracted with hexane-ethyl acetate (1:1). 
Drug compounds were separated on Nucleosil 100-5 C18 
column (Macherey Nagel, Düren, Germany) with the mo-
bile phase acetonitrile/methanol/0.05 M NaH2PO4*H
2O, pH 
6.4 buffer (6:5:19, v/v/v). The eluted substance was detect-
ed at 306 nm, 234 nm, and 204 nm (15). Serum topiramate 
concentrations were analyzed using fluorescence polar-
ization immunoassay Innofluor (Seradyn Inc., Indianapolis, 
IN, USA) on a TDx (Abbott Laboratories, Lake Bluff, IL, USA) 
analyzer. Vigabatrin and gabapentin were measured after 
derivatization by high performance liquid chromatogra-
phy (HPLC) method using a fluorescence detector (Waters, 
Milford, MA, USA). The serum concentrations of phenobar-
bital and valproate were analyzed by immunoassay on a 
Dimension Expand analyzer (Siemens, Erlangen, Germany). 
The calibrator and control samples used for HPLC meth-
od were from Chromsystems (Munich, Germany), whereas 
those used for the immunoassay were from Innofluor and 
Siemens. All analytes were evaluated through the external 
quality assessment schemes (Referenzinstitut für Bioanaly-
tik and United Kingdom National External Quality Assess-
ment Service).
Statistical analysis
Descriptive statistics was used for demographic and clinical 
data presentation. After testing for normality of data distri-
bution with D’Agostino-Pearson test, differences in steady 
state trough and dose-corrected lamotrigine concentra-
tions between therapy groups were analyzed. As the lam-
otrigine concentration was not normally distributed in the 
study population, significance of differences between the 
groups was tested with the Kruskal-Wallis test. Correlation 
analysis between parameters was performed by Spear-
man’s coefficient of rank correlation and presented as cor-
relation coefficients (rho values) with 95% confidence in-
terval (CI) and P values. The level of statistical significance 
was set at P < 0.05. All statistical analyses were performed 
using the statistical program MedCalc ver. 17.2.
rESuLTS
All median values of lamotrigine trough concentrations 
lay within the reference range (8), but median concentra-
tions of majority of other AEDs were closer to the lower 
range area (Table 2). There were significant differences in 
trough lamotrigine and dose-corrected lamotrigine con-
centrations between the four groups (P < 0.001; Figure 
2.). Patients receiving lamotrigine with valproate had the 
highest concentrations of lamotrigine even after the 
dose correction of the concentration (Table 2). Pa-
tients on lamotrigine monotherapy had the lowest 
TaBLE 1. Clinical and demographic data on 304 lamotrigine-
treated patients (126 men) with epilepsy enrolled in the study*
Parameter Value (mean±SD)
Age (years)  37 ± 14
Height (cm) 171 ± 9
Body weight (kg)  73 ± 18
Urea (mmol/L)   4.4 ± 1.4
Creatinine (μmol/L)  83.0 ± 17.4
ALT (U/L)  18.9 ± 15.1
GGT (U/L)  58.9 ± 49.9
*abbreviations: SD – standard deviation, aLT – alanine aminotrans-
ferase, GGT – gamma-glutamyl transferase.
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lamotrigine concentration. However, after the dose cor-
rection, the lowest values were observed in patients treat-
ed with lamotrigine in combination with one of the meta-
bolic inducers.
Lamotrigine concentrations varied depending on the dose 
and concomitant therapy. We evaluated the correlation 
between lamotrigine and valproate in all patient groups 
concomitantly treated with these two drugs and the cor-
relation of lamotrigine with carbamazepine, MHD, and 
phenobarbital in patients without concomitant valproate 
therapy.
There was a significant linear positive correlation between 
lamotrigine and valproate trough concentrations, which 
was even greater after the dose correction (Table 3). Com-
parison of lamotrigine with MHD and phenobarbital did 
not show any correlation for trough concentrations, but a 
significantly positive correlation was observed for carbam-
azepine and MHD after the dose correction. Nine patients 
in the groups receiving lamotrigine in combination with 
inducers or both inhibitors and inducers had phenytoin 
in their therapy, but statistical analysis was not performed 
due to the low number of these patients.
DISCuSSION
Our results confirmed the inhibitory effect of valproate 
with the resulting increase in lamotrigine concentrations. 
TaBLE 2. Serum trough- (C) and dose-corrected (C/D) antiepileptic drug (aED) concentrations in lamotrigine-treated patients with 
epilepsy*
aED concentrations (median, 5th-95th percentile)
Therapy No. of patients f C (µmol/L) C/D (µmol/L/mg)
Lamotrigine 304 3.90   8.6 (2.3-38.9) 0.062 (0.022-0.202)
monotherapy 74   6.4 (1.6-23.5) 0.065 (0.024-0.145)
 + inhibitor 37  25.9 (5.3-50.8) 0.174 (0.059-0.261)
 + inducer 138   6.5 (2.0-21.7) 0.040 (0.017-0.098)
 + inhibitor and inducer 55  15.8 (3.0-57.3) 0.094 (0.044-0.218)
politherapy
 + valproate 92 6.93 339.7 (128.9-652.9) 0.342 (0.154-0.603)
 + phenobarbital 78 4.31  69.4 (14.1-168.6) 0.246 (0.033-0.673)
 + carbamazepine 110 4.23  32.7 (18.4-53.1) 0.032 (0.018-0.073)
 + MHD 47 3.96  58.0 (22.6-97.7) 0.046 (0.018-0.111)
*abbreviations: f – conversion factor (µmol/L = mg/L x f) (8), MHD – monohydroxy metabolite of oxcarbazepine.
TaBLE 3. Correlation of serum trough- and dose-corrected concentrations of lamotrigine administered with concomitant antiepilep-
tic drug (aED) therapy
Lamotrigine (μmol/L) Lamotrigine/dose (μmol/L/mg)
aED No. of patients rho (95% CI)* P rho (95% CI)* P
Valproate 87 0.480 (0.298-0.628) <0.001 0.561 (0.383-0.699) <0.001
Carbamazepine 85 0.367 (0.166-0.538) <0.001 0.439 (0.235-0.594) <0.001
Phenobarbital 56 0.229 (0.036-0.464)  0.09 0.051 (-0.247-0.304)  0.83
MHD 33 0.228 (-0.125-0.530)  0.20 0.675 (0.415-0.833) <0.001
*rho –Spearman’s coefficient of rank correlation with 95% confidence intervals (CI).
FIGurE 2. Dose-corrected concentrations of lamotrigine 
administered with concomitant antiepileptic drugs acting as 
inhibitors or inducers. abbreviations: Lamo – lamotrigine, inhi 
– inhibitor, indu – inducer.
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Despite the dose reduction at the introduction of therapy, 
the observed lamotrigine blood concentrations were still 
higher than those when lamotrigine was administered as 
monotherapy or concomitantly with other AEDs. This find-
ing has a clinical importance due to dose-dependent side 
effects. We found a statistically significant correlation be-
tween lamotrigine and valproate trough concentrations. 
The correlation was statistically even stronger for dose-cor-
rected concentrations, which is not fully consistent with 
literature data. As valproate can double lamotrigine plas-
ma levels, some authors recommend that the initial dose 
should be reduced approximately by 50%. Kanner et al (16) 
reported that the degree of inhibition of lamotrigine clear-
ance is independent of the applied valproate dose and 
steady state valproate concentration. Some authors sug-
gest that valproate inhibition of lamotrigine clearance can 
be expected at a dose of 500 mg per day, with the mag-
nitude of inhibition diminishing at lower doses (17). How-
ever, these results were obtained in healthy volunteers 
who received rather low doses of valproate. Yamamoto et 
al (18) showed that valproate strongly inhibits lamotrigine 
metabolism, but they did not observe a significant correla-
tion between plasma lamotrigine concentrations adjusted 
to dose and valproate concentrations. These discordant re-
sults reported for different populations and ethnic groups 
may be partly explained by significant differences in vari-
ant allele frequencies of the UGT2B7 gene, ie, the frequen-
cy of the UGT 2B7*2 (802C>T) variant has been reported 
to be 48.9%-53.7% in Caucasians and 24.4%-29.3% in Japa-
nese population (19).
When we tested the correlations of lamotrigine with a 
single antiepileptic drug inducer such as carbamazepine, 
MHD, and phenobarbital, the results indicated that the 
trough lamotrigine concentrations were not in correla-
tion with trough concentrations of MHD or phenobarbi-
tal. Because patients were treated with different doses of 
AEDs, a dose correction of the concentration was under-
taken, after which the correlation reached statistical signif-
icance for carbamazepine and MHD. Oxcarbazepine may 
stimulate a more restricted range of CYP and/or UGT isoen-
zymes with weaker enzyme-inducing properties (20). Posi-
tive correlation between lamotrigine and MHD, the main 
metabolite of oxcarbazepine, may be explained by the 
main mechanism of MHD elimination, which is primarily 
by glucuronide conjugation. The primary metabolic route 
for carbamazepine is oxidation, which produces an ep-
oxide that is subsequently further oxidized to a diol (21). 
This is followed by conjugation with UGT2B7, which can 
explain the weak correlation between lamotrigine and car-
bamazepine. The induction of lamotrigine metabolism by 
carbamazepine or oxcarbazepine may result in decreased 
lamotrigine concentrations, but in the next step, carbam-
azepine/MHD and lamotrigine compete for the same en-
zymes. This can finally result in increased concentrations of 
both lamotrigine and carbamazepine/MHD (22).
We observed no effect on lamotrigine kinetics, as previ-
ously described (23), of topiramate, which is a weak in-
ducer (24), and others such as gabapentin, vigabatrin, and 
levetiracetam whose main route of elimination is renal ex-
cretion. This could be due to the small number of patients 
in each group, which did not allow drawing any firm con-
clusions.
Due to complexity of these mechanisms, it is still difficult 
to predict the final outcome of these interactions (25). Fur-
thermore, drug transporters, present at many barriers and 
organs involved in drug absorption, distribution, and ex-
cretion, play a key role in the bioavailability and concentra-
tions of many drugs, including AEDs. Additionally, the fact 
that drugs can be substrates and inhibitors or inducers of 
transporter proteins makes the pharmacokinetics of AEDs 
even more complex (26).
In conclusion, our original finding was that higher val-
proate concentration levels resulted in higher lamotrigi-
ne serum levels. This is a fact that clinicians should keep 
in mind when concomitantly prescribing these two drugs, 
since majority of their adverse effects are dose-dependent. 
Additionally, significant positive correlations between la-
motrigine, carbamazepine, and MHD concentrations in-
dicated that upon the completion of induction, a higher 
dose-corrected concentration of inducers did not further 
lower lamotrigine levels. These findings may have clinical 
significance for optimal AED dosing, since side effects of 
AEDs are dose-dependent and reinforce the view that op-
timizing lamotrigine dose in an individual patient is best 
achieved by adjunctive measurement of serum levels. 
More studies with larger sample sizes than those in our 
study are needed to validate our findings.
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